{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:41:02Z","timestamp":1789609262991,"version":"build-2803163510"},"reference-count":33,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,2,4]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>Haemolytic uraemic syndrome (HUS) is a thrombotic microangiopathy (TMA) that presents with renal insufficiency, thrombocytopaenia and microangiopathic haemolytic anaemia. Typical HUS is associated with Shiga toxin while atypical HUS (aHUS) is due to overactivation of the alternative complement pathway. aHUS has numerous causes, including drugs, with rare reports of carfilzomib, a proteasome inhibitor used in multiple myeloma, as causative agent. Cases vary in presentation, presenting a diagnostic challenge. Historically, TMAs were treated with plasma exchange. aHUS, however, is considered refractory to plasma exchange and best treated with eculizumab, a monoclonal antibody targeting C5, a terminal complement protein. We report a patient with history of multiple myeloma who presented with headaches, elevated blood pressure, petechiae, ecchymosis and haemolytic anaemia. His condition was determined to be carfilzomib-induced aHUS and he was successfully treated with eculizumab. Early detection and treatment of drug-induced aHUS is vital in reducing morbidity and mortality related to the condition.<\/jats:p>","DOI":"10.1136\/bcr-2020-239091","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T11:03:37Z","timestamp":1614337417000},"page":"e239091","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and therapeutic success"],"prefix":"10.1136","volume":"14","author":[{"given":"Alicia","family":"Darwin","sequence":"first","affiliation":[{"name":"Morsani College of Medicine, University of South Florida, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonger","family":"Malpica","sequence":"additional","affiliation":[{"name":"Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jugraj","family":"Dhanoa","sequence":"additional","affiliation":[{"name":"Internal Medicine, University of Louisville, Louisville, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[{"name":"Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA"},{"name":"Department of Hematology Oncology, Medical University of South Carolina, Charleston, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"2025082700443507000_14.2.e239091.1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001581"},{"key":"2025082700443507000_14.2.e239091.2","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical Hemolytic\u2013Uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025082700443507000_14.2.e239091.3","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-60"},{"key":"2025082700443507000_14.2.e239091.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-611335"},{"key":"2025082700443507000_14.2.e239091.5","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfv059"},{"key":"2025082700443507000_14.2.e239091.6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-15-156"},{"key":"2025082700443507000_14.2.e239091.7","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/ccr3.1214","article-title":"Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment","volume":"5","author":"Gosain","year":"2017","journal-title":"Clin Case Rep"},{"key":"2025082700443507000_14.2.e239091.8","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02210310"},{"key":"2025082700443507000_14.2.e239091.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-516237"},{"key":"2025082700443507000_14.2.e239091.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.04.007"},{"key":"2025082700443507000_14.2.e239091.11","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.5037.5037","article-title":"Fatal thrombotic microangiopathy developing within 24 hours of carfilzomib in a patient with relapsed multiple myeloma (Mm)","volume":"120","author":"Atrash","year":"2012","journal-title":"Blood"},{"key":"2025082700443507000_14.2.e239091.12","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.62","article-title":"Thrombotic microangiopathy during carfilzomib use: case series in Singapore","volume":"6","author":"Chen","year":"2016","journal-title":"Blood Cancer J"},{"key":"2025082700443507000_14.2.e239091.13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.12691\/ajmcr-7-10-5","article-title":"Late presentation of carfilzomib associated thrombotic microangiopathy","volume":"7","author":"Haddadin","year":"2019","journal-title":"Am J Med Case Rep"},{"key":"2025082700443507000_14.2.e239091.14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.nefro.2018.02.005","article-title":"Eculizumab as a treatment for atypical hemolytic syndrome secondary to carfilzomib","volume":"39","author":"Moliz","year":"2019","journal-title":"Nefrologia"},{"key":"2025082700443507000_14.2.e239091.15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018027532"},{"key":"2025082700443507000_14.2.e239091.16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.transci.2016.03.002","article-title":"Carfilzomib: a cause of drug associated thrombotic microangiopathy","volume":"54","author":"Qaqish","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"2025082700443507000_14.2.e239091.17","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21371"},{"key":"2025082700443507000_14.2.e239091.18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24447"},{"key":"2025082700443507000_14.2.e239091.19","first-page":"1","article-title":"Renal thrombotic microangiopathy associated with the use of bortezomib in a patient with multiple myeloma","volume":"2016","author":"Van Keer","year":"2016","journal-title":"Case Rep Hematol"},{"key":"2025082700443507000_14.2.e239091.20","doi-asserted-by":"crossref","first-page":"e791","DOI":"10.1016\/j.clml.2020.04.014","article-title":"Drug-Induced thrombotic microangiopathy with concurrent proteasome inhibitor use in the treatment of multiple myeloma: a case series and review of the literature","volume":"20","author":"Monteith","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025082700443507000_14.2.e239091.21","doi-asserted-by":"crossref","first-page":"E53","DOI":"10.1002\/ajh.24662","article-title":"Ixazomib-induced thrombotic microangiopathy","volume":"92","author":"Yui","year":"2017","journal-title":"Am J Hematol"},{"key":"2025082700443507000_14.2.e239091.22","doi-asserted-by":"crossref","unstructured":"Saavedra VH , Gonz\u00e1lez-Calle V , Sobejano E . Drug-Induced thrombotic microangiopathy during maintenance treatment in a patient with multiple myeloma. HemaSphere 2019;3.doi:10.1097\/HS9.0000000000000192","DOI":"10.1097\/HS9.0000000000000192"},{"key":"2025082700443507000_14.2.e239091.23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017148","article-title":"Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: a renal biopsy and autopsy case report","volume":"98","author":"Cassol","year":"2019","journal-title":"Medicine"},{"key":"2025082700443507000_14.2.e239091.24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000492033","article-title":"When to stop eculizumab in complement-mediated thrombotic microangiopathies","volume":"48","author":"Olson","year":"2018","journal-title":"Am J Nephrol"},{"key":"2025082700443507000_14.2.e239091.25","first-page":"149","article-title":"Guidelines on the use of therapeutic apheresis in clinical Practice-Evidence-Based approach from the writing Committee of the American Society for apheresis: the seventh special issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J Clin Apher"},{"key":"2025082700443507000_14.2.e239091.26","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20648"},{"key":"2025082700443507000_14.2.e239091.27","doi-asserted-by":"crossref","unstructured":"Nguyen MN , Nayernama A , Jones SC , et al . Proteasome inhibitor\u2010associated thrombotic microangiopathy: A review of cases reported to the FDA adverse event reporting system and published in the literature. Am J Hematol 2020;95.doi:10.1002\/ajh.25832","DOI":"10.1002\/ajh.25832"},{"key":"2025082700443507000_14.2.e239091.28","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012090884"},{"key":"2025082700443507000_14.2.e239091.29","first-page":"2","article-title":"Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis","volume":"14 Suppl 11","author":"Laurence","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"2025082700443507000_14.2.e239091.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2010.12.020"},{"key":"2025082700443507000_14.2.e239091.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981"},{"key":"2025082700443507000_14.2.e239091.32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5414\/CNCS109836","article-title":"Eculizumab in chemotherapy-induced thrombotic microangiopathy","volume":"8","author":"Schulte-Kemna","year":"2020","journal-title":"Clin Nephrol Case Stud"},{"key":"2025082700443507000_14.2.e239091.33","unstructured":"FDA . Highlights of prescribing information: Soliris (eculizumab), 2007."}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-239091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:44:43Z","timestamp":1756280683000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-239091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,26]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/bcr-2020-239091"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-239091","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}